Dec. 12 Quick Takes: Targeted genomic DNA insertion company Tome launches with $213M

Tome Biosciences Inc., whose programmable genomic integration technology enables the insertion of any size of DNA sequence into any targeted genomic location, raised a combined $213 million in series A and B funding from Andreessen Horowitz (a16z) Bio + Health, Arch Venture Partners, GV, Longwood Fund, Polaris Partners, Bruker Corp. (NASDAQ:BRKR), Fujifilm Holdings Corp. (Tokyo:4901), Alexandria Venture Investments and other undisclosed investors.

In-licensed from Massachusetts Institute of Technology (MIT) and discovered by co-founders Omar Abudayyeh and Jonathan Gootenberg, Tome’s PASTE technology enables targeted DNA insertions of more than 30kb without requiring double-stranded breaks, facilitating the use of endogenous promoters in the human genome to control gene expression...